Integra LifeSciences Holdings Corporation IART

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. “Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporti

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction. The Company intends to use the net proceeds from the Term Loan B, together with other sources of financing, to refinance certain of its existing indebtedness and pay associated fees and expenses. “This transa

Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients ACCLARENT AERA® Eustachian Tube Balloon Dilation System ACCLARENT AERA® Eustachian Tube Balloon Dilation System PRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry evaluating the real-worl

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Company to feature surgeon-led educational programming and technologies supporting liver surgery CUSA MicroFrance CUSA Clarity Laparoscopic Tip and MicroFrance Laparoscopic Bipolar Forceps - precision, handmade instruments created with the notion that Millimeters of Accuracy matter. PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® technology within its portfolio at the American College of Surgeons (ACS) Clinical Congress 2026, ta

Integra LifeSciences Holdings has a share price of US$16.02 after a mixed stretch that includes both a sharp multi-year decline and a solid gain this year. With the market clearly reassessing the story, the open question is whether the current Integra LifeSciences valuation is supported by the cash the business can generate over time. Over the past 5 years, the stock has fallen 77.3%, which puts the focus squarely on whether the cash flowing out of the business can justify where the shares...

Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.

What a time it’s been for Integra LifeSciences. In the past six months alone, the company’s stock price has increased by a massive 70.2%, reaching $16.26 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, Septe

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.